OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Samsung Shares Rise on $72 Billion Shareholder Return Plan 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
Add as a preferred source on Google
BUFFALO, N.Y., May 08, 2018 -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will present at the Deutsche Bank’s 43rd Annual Health Care Conference in Boston, MA, on Tuesday, May 8th, at 2:10 pm EDT.
The presentation will be webcasted, and can be accessed at the Investor Relations section of the Company’s website, located at www.athenex.com. An archive will be available at this website until August 6, 2018.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. Athenex’s Oncology Innovation Platform generates clinical candidates through an extensive understanding of kinases, including novel binding sites and human absorption biology, as well as through the application of Athenex’s proprietary research and selection processes in the lab. The Company’s current clinical pipeline is derived from two different platform technologies Athenex calls Orascovery and Src Kinase Inhibition. The Orascovery platform is based on the novel oral P-glycoprotein pump inhibitor molecule HM30181A, through which Athenex is able to facilitate oral absorption of traditional cytotoxics, which Athenex believes may offer improved patient tolerability and efficacy as compared to IV administration of the same cytotoxics. The Orascovery platform was developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi. The Src Kinase Inhibition platform refers to novel small molecule compounds that have multiple mechanisms of action, including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization during cell division. Athenex believes the combination of these mechanisms of action provides a broader range of anti-cancer activity as compared to either mechanism of action alone. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan and multiple locations in Chongqing, China.
CONTACT:
Jim Polson
Tel: +1-716-427-2952
Athenex, Inc.
